BPC-157 + TB-500: Scientific Profile

Publicado el 28 de diciembre de 2025 · Actualizado el 18 de septiembre de 2026

Blend of two research peptides: BPC-157 (cytoprotective pentadecapeptide, VEGF/eNOS angiogenesis) + TB-500 (N-acetylated fragment Ac-LKKTETQ of Thymosin β4 that sequesters G-actin and modulates cell migration).

The BPC-157 + TB-500 blend brings together two synthetic research peptides with complementary mechanisms. BPC-157 is a 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV, CAS 137525-51-0; C62H98N16O22; 1419.55 Da) derived from a human gastric protective protein (Body Protection Compound); in preclinical models it is associated with angiogenesis and revascularization through VEGF, VEGFR2, eNOS, nitric oxide, and the PI3K/Akt pathway. TB-500 is the N-acetylated active fragment of Thymosin β4: a 7-amino-acid heptapeptide with sequence Ac-LKKTETQ (residues 17-23 of Tβ4, CAS 885340-08-9) that sequesters G-actin and promotes cell migration and endothelial progenitor cells (EPCs). The rationale for the combination integrates the angiogenic signaling of BPC-157 with the cellular mobilization of TB-500 in tissue repair studies. There is no regulatory approval or controlled clinical trials of the combination; it is a reagent for research use only (RUO). As this is a blend, single values of CAS, formula, or molecular weight do not apply at the compound level.

Mechanism of action

The BPC-157 + TB-500 blend combines two distinct but complementary pharmacological profiles. BPC-157 promotes local healing through: stimulation of eNOS and production of NO, upregulation of VEGF/VEGFR2, activation of the FAK-paxillin pathway in myocytes, gastrointestinal cytoprotection via stabilization of the epithelial barrier, and modulation of the brain-gut axis with neuroprotective effects. TB-500 acts systemically via: sequestration of G-actin with dynamic release for polymerization at sites of migration, promotion of migration of endothelial progenitor cells (EPCs) and muscle satellite cells, induction of angiogenesis with upregulation of VEGF, inflammatory modulation (↓TNF-α, IL-6; ↑Bcl-2, ↓caspase-9), and activation of epicardial Sca-1+ stem cells in cardiac models. The proposed synergy operates on three axes: (1) BPC-157 prepares the local bed with receptive vasculature and extracellular matrix; (2) TB-500 mobilizes reparative cells from systemic compartments; (3) both peptides suppress apoptosis and deleterious inflammation. They have not been characterized pharmacokinetically as a combination.

Mechanism summary

BPC-157 (a pentadecapeptide) drives angiogenesis and revascularization via VEGF, VEGFR2, eNOS and nitric oxide (Src-Caveolin-1-eNOS, PI3K/Akt); TB-500 (the N-acetylated heptapeptide Ac-LKKTETQ of Thymosin β4) sequesters G-actin and modulates cell migration and EPCs. A combination for research on tissue repair.

Clinical Studies (6)

There is no peer-reviewed literature on BPC-157 + TB-500 as a combination. What follows is the literature for each component separately:

About BPC-157: Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats (Xue, et al. · World Journal of Gastroenterology · 2004) PMID 15052688.
About TB-500: Thymosin beta4 accelerates wound healing (Malinda, et al. · Journal of Investigative Dermatology · 1999) PMID 10469335.
About BPC-157: Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157 (Sikiric, et al. · Current Medicinal Chemistry · 2012) PMID 22300085.
About TB-500: Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications (Goldstein, et al. · Expert Opinion on Biological Therapy · 2012) PMID 22074294.
About BPC-157: The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (Chang, et al. · Journal of Applied Physiology · 2011) PMID 21030672.
About TB-500: Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury (Sosne, et al. · Experimental Eye Research · 2002) PMID 11950239.

Warnings

BPC-157 + TB-500 is a research-use-only (RUO) compound; the following warnings and handling considerations apply to its laboratory use:

Experimental combination without regulatory approval or published clinical trials
No joint pharmacokinetic characterization
Amplified theoretical risk of promoting tumor angiogenesis
Synergy data based on a mechanistic hypothesis, not on direct clinical evidence
For exclusive use in controlled preclinical research
Active neoplasms (theoretical risk of tumor promotion via VEGF)
Hypersensitivity to any component
Pregnancy and lactation (no data)

Technical data

Compound type: peptide_blend
Storage: -20 °C liofilizado; 2-8 °C reconstituido
Shelf life (lyophilized): 24 months at 2-8°C
Shelf life (reconstituted): 14-21 days at 2-8°C with bacteriostatic preservative
Light-sensitive: No

Available for research

BPC-157 + TB-500 is available as a research reagent (RUO) with HPLC-verified purity and COA per batch:

BPC-157 + TB-500

Frequently asked questions about BPC-157 + TB-500

What is BPC-157 + TB-500?

What is the mechanism of action of BPC-157 + TB-500?

What is BPC-157 + TB-500 investigated for?

In preclinical research, BPC-157 + TB-500 is studied mainly in: Research on connective tissue repair; Models of complex wound healing; Studies of systemic angiogenesis. Material exclusively for scientific research.

How is BPC-157 + TB-500 stored?

Condiciones de conservación: -20 °C liofilizado; 2-8 °C reconstituido; estabilidad liofilizado: 24 meses a 2-8°C; una vez reconstituido: 14-21 días a 2-8°C con conservante bacteriostático.

What routes of administration are studied for BPC-157 + TB-500?

In the research models the following are described: Subcutaneous. Use is exclusively for scientific research.

What precautions should be considered with BPC-157 + TB-500?

BPC-157 + TB-500 is material for research use only. Experimental combination without regulatory approval or published clinical trials. No joint pharmacokinetic characterization.